Submitting content and format of the C3TI Demonstration Program Proposal
Similar Posts
FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a history of sino-nasal surgery or for whom surgery is not advisable. This is the first approval forHuman Drug Compounding
Compounded drugs can serve an important medical need for certain patients, they also present a risk to patients.Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.Update: FDA Encourages the Public to Follow Established Choking Rescue Protocols – FDA Safety Communication
These choking rescue protocols include abdominal thrusts (also called the “Heimlich” maneuver) for children and adults but not anti-choking devices.Friendly’s Issues Allergy Alert on Undeclared Soy/Wheat in Friendly’s Cookies & Cream Ice Cream
Friendly’s Ice Cream is voluntarily recalling a limited quantity (324 cartons) of 48 fl. oz. Cookies & Cream ice cream because of undeclared soy and wheat. The recalled product was mistakenly packaged in Friendly’s Vanilla Bean ice cream cartons with a Cookies & Cream lid. People who have an allergyEmerging Drug Safety Technology Meetings (EDSTM)
CDER has established a meeting program called the Emerging Drug Safety Technology Meeting (EDSTM) program. Learn more.